Kaposi Sarcoma

A roundup of FDA oncology news from October 2013

By

The FDA asked the manufacturer of ponatinib (Iclusig) to suspend marketing and sales of the drug, hydrocodone bitartrate extended-release capsules (Zohydro ER) gained FDA approval, and other FDA actions.

Doxil shortage speeds approval of generic version

After expedited review, the FDA okays the first generic version of Doxil (doxorubicin hydrochloride liposome injection), now in short supply.

Cutaneous melanoma begets cutaneous melanoma

Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs